Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral paclitaxel bests IV version for tumor response, neuropathy incidence in mBC

Publish date:: December 19, 2019

Key clinical point: Oral paclitaxel plus encequidar improves outcomes and reduces neuropathy versus intravenous paclitaxel in women with metastatic breast cancer.
Major finding: Confirmed tumor response rates in the modified intent-to-treat population were 40.4% and 25.5% with oral versus intravenous paclitaxel (absolute improvement, 14.8%).
Study details: A phase 3, open-label study of 402 patients.
Disclosures: The study was funded by Athenex, the maker of the oral form of paclitaxel. Dr. Umanzor reported having no conflicts of interest.

Citation:

Umanzor G. SABCS 2019, Abstract GS6-01.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,